Microbial Antigen Delivery 2.0

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccine Adjuvants".

Deadline for manuscript submissions: closed (10 July 2021) | Viewed by 3576

Special Issue Editors


E-Mail Website
Guest Editor
Department of Poultry Science (Microbiology), North Carolina State University, Raleigh, NC 27695, USA
Interests: microbiology/infectious diseases; salmonella vaccines; synbiotics and immune responses; molecular biology; microbiome; metabolome; free radicals in biology and medicine

E-Mail
Guest Editor
Etna Biotech S.r.l, Z.I. Blocco Palma I, Stradale V. Lancia, 57, 95121 Catania, Italy
Interests: vaccine; adjuvant; immunology; biotechnology; virosome; antibody; antigens; recombinant proteins; in silico trial

Special Issue Information

Dear Colleagues,

Historical vaccines based on whole microorganisms, either live attenuated or killed, with their successful long track record for safety and efficacy, are considered one of the most important public health interventions to tackle infectious diseases. However, for many pathogens, there are still no vaccines available. Moreover, some of the licensed vaccines show suboptimal efficacy or are not recommended for use in high-risk population groups.

The growing demand for new safer, more efficacious and affordable vaccines has resulted in a shift in research to focus mainly on selected and well characterized antigens and epitopes which are very often low immunogenicity when administered alone. To meet the associated challenges, the knowledge gathered on microbial antigen delivery and their implementation through innovative technologies represent the key points to transforming a low immunogenicity antigen into an efficacious vaccine formulation. Fueled by the recent advances in translational medicine, immunology, molecular biology, bioinformatics, chemistry, and biophysics, innovative delivery systems such as involving recombinant vectors, virus-like particles, nanoparticles, emulsions, and other vehicles have been tailored to elicit a proper and long-lasting host immune response to prevent or to treat the infectious agent. The growing awareness of this aspect is underlined by the increasing numbers of publications.
The aim of this Special Issue is to present novel insights and recent advances in the field of microbial antigen delivery, including discovery, development, manufacturing, and regulatory perspectives on new vaccine formulations.

Prof. Hosni Hassan
Dr. Epifanio Fichera
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Vaccine
  • Adjuvant
  • Immunogenicity
  • Delivery system
  • Recombinant vaccine
  • Nanoparticles

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 1726 KiB  
Article
Attenuated Salmonella enterica Serovar Typhimurium, Strain NC983, Is Immunogenic, and Protective against Virulent Typhimurium Challenges in Mice
by Bryan Troxell, Mary Mendoza, Rizwana Ali, Matthew Koci and Hosni Hassan
Vaccines 2020, 8(4), 646; https://doi.org/10.3390/vaccines8040646 - 3 Nov 2020
Cited by 2 | Viewed by 2928
Abstract
Non-typhoidal Salmonella (NTS) serovars are significant health burden worldwide. Although much effort has been devoted to developing typhoid-based vaccines for humans, currently there is no NTS vaccine available. Presented here is the efficacy of a live attenuated serovar Typhimurium strain (NC983). Oral delivery [...] Read more.
Non-typhoidal Salmonella (NTS) serovars are significant health burden worldwide. Although much effort has been devoted to developing typhoid-based vaccines for humans, currently there is no NTS vaccine available. Presented here is the efficacy of a live attenuated serovar Typhimurium strain (NC983). Oral delivery of strain NC983 was capable of fully protecting C57BL/6 and BALB/c mice against challenge with virulent Typhimurium. Strain NC983 was found to elicit an anti-Typhimurium IgG response following administration of vaccine and boosting doses. Furthermore, in competition experiments with virulent S. Typhimurium (ATCC 14028), NC983 was highly defective in colonization of the murine liver and spleen. Collectively, these results indicate that strain NC983 is a potential live attenuated vaccine strain that warrants further development. Full article
(This article belongs to the Special Issue Microbial Antigen Delivery 2.0)
Show Figures

Figure 1

Back to TopTop